Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

Hassanein M, Atenafu EG, Schuh AC, Yee KW, Minden MD, Schimmer AD, Gupta V, Brandwein JM. High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leuk Res. 2013 May; 37(5):556-60.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.